Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Vet Parasitol ; 327: 110113, 2024 Apr.
Article in English | MEDLINE | ID: mdl-38232512

ABSTRACT

In this study, we present the preparation, stability, and in vivo fasciolicidal activity of three new intramuscular formulations in sheep of a prodrug based on triclabendazole, named fosfatriclaben. The new formulations were ready-to-use aqueous solutions with volumes recommended for intramuscular administration in sheep. The use of poloxamers (P-407 and P-188) and polysorbates (PS-20 and PS-80) in the new formulations improved the aqueous solubility of fosfatriclaben by 8-fold at pH 7.4. High-performance liquid chromatography with UV detection was used to evaluate the stability of fosfatriclaben in the three formulations. High recovery (> 90%) of fosfatriclaben was found for all formulations after exposure at 57 ± 2 °C for 50 h. The three intramuscular formulations showed high fasciolicidal activity at a dose of 6 mg/kg, which was equivalent to the triclabendazole content. The fasciolicidal activity of fosfatriclaben was similar to commercial oral (Fasimec®) and intramuscular (Endovet®) triclabendazole formulations at a dose of 12 mg/kg. In the in vivo experiments, all formulations administered intramuscularly reduced egg excretion by 100%, and formulations F1, F2, and F3 presented fasciolicidal activities of 100%, 100%, and 99.6%, respectively.


Subject(s)
Anthelmintics , Fasciola hepatica , Fascioliasis , Prodrugs , Sheep Diseases , Animals , Sheep , Triclabendazole , Fascioliasis/veterinary , Anthelmintics/therapeutic use , Prodrugs/chemistry , Benzimidazoles/therapeutic use , Sheep Diseases/drug therapy , Water/chemistry
2.
Molecules ; 22(12)2017 11 24.
Article in English | MEDLINE | ID: mdl-29186784

ABSTRACT

Human African Trypanosomiasis (HAT), a disease that provokes 2184 new cases a year in Sub-Saharan Africa, is caused by Trypanosoma brucei. Current treatments are limited, highly toxic, and parasite strains resistant to them are emerging. Therefore, there is an urgency to find new drugs against HAT. In this context, T. brucei depends on glycolysis as the unique source for ATP supply; therefore, the enzyme triosephosphate isomerase (TIM) is an attractive target for drug design. In the present work, three new benzimidazole derivatives were found as TbTIM inactivators (compounds 1, 2 and 3) with an I50 value of 84, 82 and 73 µM, respectively. Kinetic analyses indicated that the three molecules were selective when tested against human TIM (HsTIM) activity. Additionally, to study their binding mode in TbTIM, we performed a 100 ns molecular dynamics simulation of TbTIM-inactivator complexes. Simulations showed that the binding of compounds disturbs the structure of the protein, affecting the conformations of important domains such as loop 6 and loop 8. In addition, the physicochemical and drug-like parameters showed by the three compounds suggest a good oral absorption. In conclusion, these molecules will serve as a guide to design more potent inactivators that could be used to obtain new drugs against HAT.


Subject(s)
Benzimidazoles/chemical synthesis , Models, Molecular , Triose-Phosphate Isomerase/antagonists & inhibitors , Trypanocidal Agents/chemical synthesis , Trypanosoma brucei brucei/drug effects , Benzimidazoles/pharmacology , Drug Design , Humans , Kinetics , Protein Binding , Protein Conformation , Species Specificity , Thermodynamics , Triose-Phosphate Isomerase/metabolism , Trypanocidal Agents/pharmacology , Trypanosoma brucei brucei/enzymology , Trypanosomiasis, African/drug therapy
3.
Chem Biol Drug Des ; 76(3): 269-76, 2010 Sep 01.
Article in English | MEDLINE | ID: mdl-20572809

ABSTRACT

Protein kinase B (PKB/AKT) is an attractive therapeutic target in anticancer drug development. We have recently identified by docking-based virtual screening a low micromolar AKT-2 inhibitor. Additionally, the virtual screening hit represents a novel AKT-2 inhibitor scaffold. In this work, we discuss a structure-based design strategy toward the optimization of this hit. Following this strategy and using a herein validated docking protocol, we conducted the design of novel compounds with expected improved activity over the parent compound. The newly designed molecules have high predicted affinity for AKT-2; are synthetically accessible and are contained within the kinase-relevant property space.


Subject(s)
Antineoplastic Agents/chemistry , Protein Kinase Inhibitors/chemistry , Proto-Oncogene Proteins c-akt/antagonists & inhibitors , Antineoplastic Agents/metabolism , Crystallography, X-Ray , Drug Discovery , Models, Molecular , Protein Kinase Inhibitors/metabolism , Protein Structure, Tertiary , Proto-Oncogene Proteins c-akt/chemistry , Proto-Oncogene Proteins c-akt/metabolism , Structure-Activity Relationship
4.
Int J Biochem Cell Biol ; 42(2): 287-96, 2010 Feb.
Article in English | MEDLINE | ID: mdl-19914391

ABSTRACT

Cirrhosis is a complex process that involves a dynamic modification of liver cell phenotype associated to gene expression changes. This study investigates the reversing capacity of an adenosine derivative compound (IFC305) on a rat model of liver cirrhosis and gene expression changes associated with it. Rats were treated with IFC305 or saline for 5 or 10 weeks after cirrhosis induction (CCl(4) treatment for 10 weeks). Fibrosis score, collagenase activity and amount of hepatic stellate cells (HSC, activated and with a lipid-storing phenotype) were measured in livers. In addition, gene expression analysis was performed using 5K DNA microarrays and quantitative RT-PCR. Treatment of cirrhotic rats with IFC305 for 5 or 10 weeks compared to saline control, induced: (1) reduction of fibrosis (50-70%) and of collagen, of alpha-SMA and desmin proteins, as well as of activated HSCs in liver, (2) increased collagenase activity and cell number of lipid-storing HSC, (3) improved serum parameters of liver function, such as reduced activity of aminotransferases and bilirubin. Expression of 413 differential genes, deregulated in cirrhotic samples, tended to be normalized by IFC305 treatment. Some genes modulated at transcript level by IFC305 were Tgfb1, Fn1, Col1a1, C9, Apoa1, Ass1, Cps1, and Pparg. The present study shows that IFC305 reverses liver fibrosis through modulation of adipogenic and fibrosis-related genes and by ameliorating hepatic function. Thus, understanding of the anti-cirrhotic effect of IFC305 might have therapeutical potential in patients with cirrhosis.


Subject(s)
Adenosine/analogs & derivatives , Adenosine/pharmacology , Carbon Tetrachloride/pharmacology , Gene Expression Regulation/drug effects , Liver Cirrhosis/chemically induced , Liver Cirrhosis/drug therapy , Adenosine/therapeutic use , Animals , Aspartic Acid/analogs & derivatives , Gene Expression Profiling , Hepatic Stellate Cells/drug effects , Hepatic Stellate Cells/metabolism , In Vitro Techniques , Kinetics , Lipid Metabolism/drug effects , Liver/drug effects , Liver/enzymology , Liver/metabolism , Liver/physiopathology , Liver Cirrhosis/metabolism , Liver Cirrhosis/physiopathology , Male , Rats , Rats, Wistar , Recovery of Function/drug effects , Reverse Transcriptase Polymerase Chain Reaction , Urea/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...